| Entry |
|
|---|
| Name |
Ibritumomab tiuxetan (USAN/INN);
Ibritumomab tiuxetan (genetical recombination) (JAN);
Zevalin (TN) |
|---|
| Product |
ZEVALIN (Acrotech Biopharma LLC) |
|---|
| Remark |
| Therapeutic category: | 4291 4300 |
|
|---|
| Efficacy |
Antineoplastic, Radioactive agent, Anti-CD20 antibody |
|---|
| Disease |
Low-grade or follicular non-Hodgkin's lymphoma [DS:H00005 H00011 H01613] |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
CD20 [HSA:931] [KO:K06466] |
|---|
| Pathway |
| hsa04640 | Hematopoietic cell lineage |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V10 THERAPEUTIC RADIOPHARMACEUTICALS
V10X OTHER THERAPEUTIC RADIOPHARMACEUTICALS
V10XX Various therapeutic radiopharmaceuticals
V10XX02 Ibritumomab tiuxetan (90Y)
D04489 Ibritumomab tiuxetan (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D04489 Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
43 Radioactive drugs
430 Radioactive drugs
4300 Radioactive drugs
D04489 Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D04489 Ibritumomab tiuxetan (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04489
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D04489
|
|---|
| Other DBs |
|
|---|